Background: Ovarian cancer is the leading cause of death from gynecological malignancies and the fourth most frequent fatal malignancy in women. Despite improved surgical techniques as many as 20% of women with early stage disease will eventually relapse and die from their disease. The post-operative management of these women remains controversial. Here we present the long term follow-up data of our previously published study, as well as the incidence of second primary malignancies in these women.
Background: Ovarian cancer is the leading cause of death from gynecological malignancies and the fourth most frequent fatal malignancy in women. Despite improved surgical techniques as many as 20% of women with early stage disease will eventually relapse and die from their disease. The post-operative management of these women remains controversial. Here we present the long term follow-up data of our previously published study, as well as the incidence of second primary malignancies in these women.
Patients and methods; Two hundred fifty-seven eligible patients with stage I, IIA 'high risk' ovarian carcinoma and IIB, IIIO (disease confined to pelvis) were randomized to either whole abdominal radiotherapy 2,250 rads in ten fractions (107 patients), melphalan 8 mg/m 2 /d x 4 weeks x 18 courses (106 patients) or intraperitoneal chromic phosphate 10-20 mCi (44 patients). All patients were initially treated with pelvic radiotherapy.
Results: Overall survival estimates at 10 years were: 45% in the whole abdominal radiotherapy arm; 49% in the melphalan arm and 50% in the intraperitoneal chromic phosphate arm (P -0.30). Relapse-free survival estimates at 10 years were: 50% in the whole abdominal radiotherapy arm, 62% in the melphalan arm and 51% in the chromic phosphate arm (P = 0.147). Long term follow-up has not demonstrated a significant difference between treatment arms. Second primary malignancies developed in 29 women (11%) after 2,229 person years of follow-up. This compares to 18.7 second primary malignancies which would have been expected in this group of age-matched controls and was statistically significant (P = 0.018). There was no significant difference in the total number of second primary malignancies between treatment arms. Melphalan appeared to be associated with an increased risk of developing leukemia/myelodysplastic syndrome compared to the whole abdominal radiotherapy arm (P = 0.06).
Conclusions: Long-term follow-up has not demonstrated a significant difference in overall or disease free survival between treatment arms. An excess of second primary malignancies (35%) was observed suggesting that lifelong surveillance is required in this population. Further research with newer treatment programs are needed to improve the cure rates in this population.
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Introduction
Epithelial ovarian carcinoma is the leading cause of death from gynecological malignancies and the fourth most frequent fatal malignancy in women [1] . While the majority of women present with advanced ovarian cancer, those who present with disease confined to the pelvis are potentially curable. Improved surgical staging and treatment of early stage disease has led to long term survival rates of 80%-95% [2, 3] . Unfortunately as many as 20%-30% of women with early stage I disease will eventually relapse and die from their disease [4] . Clearly there is a subgroup of women with early stage disease who potentially may benefit from adjuvant treatment.
The post-operative management for this group of women remains controversial [5] . Several treatment options in the literature have been explored including: abdominopelvic radiotherapy, intraperitoneal radioactive chromic phosphate and systemic chemotherapy [3, [6] [7] [8] [9] [10] [11] [12] .
No clear consensus exists [13] . Recommendations for these women is hampered by the potential long-term complications of adjuvant therapy in a cancer where the prognosis is already reasonable.
There is limited data in the literature on the longterm follow-up of women treated for early stage ovarian cancer. Long-term data is needed to identify women who have relapsed as well as to assess long-term toxicities such as second primary malignancies. This information might influence future treatment options for women with early stage disease. In November 1985 the National Cancer Institute of Canada -Clinical Trials Group reported the results of a randomized control trial of whole abdominal radiotherapy, melphalan or intraperitoneal chromic phosphate for patients with poor prognosis early stage ovarian cancer [9] . We present an update of our previous analysis including overall and disease-free survival as well as the incidence of second primary malignancies.
Patients and methods
The methodology and eligibility criteria have been previously described [9] . Briefly, patients were eligible if they had FIGO (1971 classification) stage I or IIA ovarian cancer with either rupture of malignant ovarian cysts, poorly differentiated tumour, extracystic excrescences or positive cytology. Patients with stage IIB or III disease with disease confined to the pelvis were also included. Total abdominal hysterectomy and bilateral salpingo-oophrectomy must have been performed, but no prior chemotherapy or radiotherapy could have been administered. Patients were randomly assigned to one of three treatment arms: whole abdominal radiotherapy (2,250 rad in 20 fractions), oral melphalan (8 mg/m 2 /d x 4 days every 4 weeks x 18 courses), or intraperitoneal chromic phosphate (10-20 mCi, single dose). All patients received pelvic irradiation. In April 1980, accrual to the pelvic radiotherapy and intraperitoneal chromic phosphate arm was discontinued after 44 patients had been randomized, due to unacceptably high toxicity. Major complications including diarrhea and bowel obstructions were seen in 29% of patients [14] . Accrual to the other two arms was closed once the original accrual goal was met: 106 eligible patients on the melphalan arm and 107 patients on the whole abdominal radiation arm. The required follow-up examinations were every 2 months for the first 18 months, every 3 months up to 3 years, every 6 months up to 5 years, then yearly thereafter.
Survival was measured from the date of randomization until death or last follow-up. Relapse free-survival was calculated from the date of randomization to the first documented evidence of treatment failure. The Kaplan-Meier method was adopted to estimate survival. A Fisher's exact test was performed to compare the incidence of hematological malignancies in the melphalan and whole abdominal radiotherapy arms. A chi-square analysis was performed to compare observed versus expected malignancy rates in this population. Cancer incidence rates in age matched Canadian women were multiplied by person years at risk to determine the expected number of malignancies in this population. The median follow-up at the time of the current analysis (January 1996) was 13.5 years.
Results
From May 1975 to March 1984, a total of 284 patients were enrolled from 12 participating Canadian centers. Twenty-seven patients (10%) were considered initially ineligible; ten due to extrapelvic stage III or stage IV disease; nine because of incomplete surgery; three because on review of the pathology the disease was not felt to be due to ovarian cancer; two because of prior radiotherapy; two because the attending physician was not a study participant; and one because of a threemonth delay between surgery and radiation. There were 257 eligible patients included in this analysis.
Overall survival and relapse-free survival
In our 1986 analysis we found no significant difference in overall survival between the treatment arms: 62% in the whole abdominal radiotherapy arm; 61% in the melphalan arm and 66% in the chromic phosphate arm (P -0.49). At the time of this analysis 44% of patients were still alive. The overall survival estimates at 10 years were similar in the 3 cohorts: 45% in the whole abdominal radiotherapy arm; 49% in the melphalan arm and 50% in the intraperitoneal arm (P = 0.301) (Figure 1 ).
There was no significant difference in relapse-free survival between treatment arms in our 1986 analysis.
In that analysis we reported that melphalan appeared to have a marginal but not statistically significant benefit compared to the whole abdominal radiotherapy arm (P -0.06). This trend was again demonstrated in our updated analysis with an estimated relapse-free survival at 10 years of 50% in the whole abdominal radiotherapy arm and 62% in the melphalan arm (P = 0.055, log-rank test). The relapse-free survival in the chromic phosphate arm was 51% (Figure 2 ).
Second malignancies
Second primary malignancies have developed in 29 women (11%) after 2229 person years of follow-up; 24 solid tumours and 5 hematological malignancies ( (P = 0.396). The median age at time of diagnosis of a second primary malignancy was 62 years (range 45-80) and the median time from diagnosis of ovarian cancer to the development of a second primary was 7.5 years (range 1-17). Median survival from the time of diagnosis of the second primary malignancy was 11 months (range 0-72). Fifteen patients were deceased at the time of this analysis. Breast cancer was the most common second primary malignancy occurring in seven patients followed by lung cancer (four patients); skin cancer (three patients) and colorectal cancer (three patients). Less common tumour types included: thryoid (one patient), pancreas (one patient), glioblastoma multiforme (one patient), mycosis fungoides (one patient) and multiple myeloma (one patient). Leiomyosarcoma developed in two patients: one patient with leiomyosarcoma of the abdominal wall was treated with whole abdominal radiotherapy.
In this analysis 29 women developed second primary malignancies of which 24 were solid tumours. This compares to 18.7 second primary malignancies which would have been expected in this group of patients compared to age-matched controls. This was statistically significant (P = 0.018) and represented a relative risk of a developing a second primary malignancy of 1.55. Excess malignancies were reported in women aged 40-49 (2 observed vs. 0.78 expected), 50-59 (7 observed vs. 3.4 expected), 60-69 (10 observed vs. 7.1 expected) and in women aged 70-79 (8 observed vs. 6.0 expected).
In our 1986 analysis, we reported that four patients treated with melphalan (two patients were originally assigned to other treatment arms) developed either a myelodysplastic syndrome (one patient) or acute myelogenous leukemia (three patients). As of January 1996, one additional patient in the melphalan arm was reported to have developed acute myelogenous leukemia. The median time from diagnosis of ovarian cancer to diagnosis of leukemkia/myelodysplastic syndrome was five years (range 1-8 years). The median survival of patients from the time of diagnosis of their second primary malignancy was eight months (range 0-14). Three of the five women with hematological malignancies had stage IA/B disease. No cases were observed in women treated with intraperitoneal chromic phosphate or whole abdominal radiotherapy. Melphalan appeared to be associated with an increased risk of developing leukemia/myelodysplastic syndrome compared to the whole abdominal radiotherapy arm although this was not statistically significant (P -0.06).
Second solid primary malignancies have developed in 24 patients compared to 12 patients reported in our 1986 analysis. Patients treated with melphalan accounted for 12 second primary malignancies while 9 occurred in patients treated with whole abdominal radiotherapy and 3 occurred in the chromic phosphate arm. There was no statistically significant difference in the total number of second primary malignancies between treatment arms
Discussion
In this updated analysis we found no significant difference in overall survival between the treatment arms. This is similar to our earlier analysis reported in 1986. Relapsefree survival was marginally superior in the melphalan arm in both analysis but did not reach statistical significance.
In this study we report a 35% excess of second primary malignancies (29 observed vs. 18.5 expected) in women treated for ovarian cancer compared to agematched controls. Melphalan appeared to be associated with an increased risk of developing leukemia/myelodysplastic syndrome although this was not statistically significant. Previous studies have clearly demonstrated that patients who have received chemotherapy with alkylating agents for ovarian cancer have an increased risk of acute leukemia, particularly the myeloid type [15] [16] [17] . The lack of statistical significance demonstrated in this study may be attributed to the small number of patients and consequently few events.
Second primary malignancies following treatment for gynecological malignancies have been reported to occur in the breast, endometrium, colon, rectum, anus, vagina, bladder, kidney and lung [18, 19] . Few studies have addressed the long term complications associated with anti-cancer treatment in women with ovarian cancer. A retrospective analysis of 32,351 women diagnosed with ovarian cancer reported a significant elevated risk of developing solid tumours (RR 1.28) in women who had survived greater than 15 years. Based on this data the authors concluded that one in five women would be expected to develop a new malignancy within two decades of their diagnosis of ovarian cancer [20] . This is similar to our long term data which demonstrated an increased risk of developing a second primary tumour (RR 1.55) at a median of 13.5 years. This data would suggest that an increased awareness is necessary in this patient population as the risk of developing a second primary malignancy may exist for many years. Patients should be followed clinically and appropriate investigations initiated promptly based on reported symptoms.
While one can suggest that anti-cancer therapy is likely responsible for the increased relative risk of developing a second primary malignancy in these women, it is also possible that these women may be predisposed to developing other cancers on the basis of a undefined genetic predisposition or co-carcinogenesis independent of the treatment effect. This would be difficult to separate from the long term risk associated with anticancer therapy and for the time being remains theoretical.
The excess risk of developing a second primary malignancy may be acceptable with treatment of malignancies with a relatively poor prognosis. Anti-cancer treatment in malignancies with more favourable survival rates will have to consider the potential risk associated with such treatments. One might anticipate the emergence of solid tumour excesses in patients exposed to carcinogenic agents as both survival and long-term follow-up increases in this population.
Further studies are needed to clarify the carcinogenic risks associated with modern therapies for ovarian cancer.
Future trials should help clarify who we should be treating and what the ideal adjuvant therapy should be. A number of studies are currently addressing these issues. Gynecologic Oncology Group Protocol 157 is a randomized control trial of three versus six cycles of carboplatin and paclitaxel in women with early stage ovarian cancer. The International Collaborative Ovarian Neoplasm (ICON-1, EU-91002) study randomizes patients with fully resected early stage ovarian cancer to six cycles of cisplatin based adjuvant chemotherapy or observation. A similar European trial (EORTC-55904), randomizes women with early stage disease to observation or four to six cycles of cisplatin based chemotherapy. The results of these prospective trials should help clarify the role of adjuvant therapy in this population.
